Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100

Cancer Research

Volumn 69, Issue 19, 2009, Pages 7784-7792

  Van Stipdonk, Marianne J B ^a   Badia Martinez, Daniel ^b   Sluijter, Marjolein ^a   Offringa, Rienk ^a   Van Hall, Thorbald ^a   Achour, Adnane ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLVALYLGLYCYLALANYLLEUCYLGLUTAMYLGLYCYLPROLYLARGINYL ASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCYLGLYCYLVALYLPROLYL ARGINYLGLUTAMINYLLEUCINE; ALANYLVALYLGLYCYLALANYLLEUCYLGLUTAMYLGLYCYLSERYLARGINYL ASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCYLGLYCYLVALYLPROLYL ARGINYLGLUTAMINYLLEUCINE; ALANYLVALYLGLYCYLALANYLLEUCYLLYSYLVALYLPROLYLARGINYL ASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCYLGLYCYLVALYLPROLYLARGINYL GLUTAMINYLLEUCINE; CD8 ANTIGEN; EPITOPE; GLYCINE; GLYCOPROTEIN GP 100; IMIQUIMOD; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; PEPTIDE; PROLINE; TUMOR ANTIGEN; TYROSINE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VACCINATION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; EPITOPES; GP100 MELANOMA ANTIGEN; H-2 ANTIGENS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70350244535     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1724     Document Type: Article

References (42)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915 (Pubitemid 39273730)
2. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64. (Pubitemid 35398865)
3. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
4. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351-360
5. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-414 (Pubitemid 46696551)
6. Borbulevych OY, Baxter TK, Yu Z, Restifo NP, Baker BM. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol 2005;174:4812-4820 (Pubitemid 40504564)
7. Chen JL, Stewart-Jones G, Bossi G, et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 2005;201:1243-1255 (Pubitemid 40629068)
8. Webb AI, Dunstone MA, Chen W, et al. Functional and structural characteristics of NY-ESO-1-related HLA A2- restricted epitopes and the design of a novel immunogenic analogue. J Biol Chem 2004;279:23438-23446 (Pubitemid 38685654)
9. Denkberg G, Klechevsky E, Reiter Y. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J Immunol 2002;169:4399-4407 (Pubitemid 35178214)
10. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008;105:3849-3854 (Pubitemid 351723488)
11. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154: 3961-3968
12. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-286
13. Watts S, Wheeler C, Morse R, Goodenow RS. Amino acid comparison of the class I antigens of mouse major histocompatibility complex. Immunogenetics 1989;30: 390-392 (Pubitemid 19269942)
14. Feltkamp MC, Vierboom MP, Kast WM, Melief CJ. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol Immunol 1994;31:1391-1401
15. Sijts AJ, De Bruijn ML, Ressing ME, et al. Identification of an H-2 Kb-presented Moloney murine leukemia virus cytotoxic T-lymphocyte epitope that displays enhanced recognition in H-2 Db mutant bm13 mice. J Virol 1994;68:6038-6046 (Pubitemid 2129760)
16. Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;185: 317-328 (Pubitemid 27078288)
17. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145:185-192
18. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 2007;179:5033-5040
19. Achour A, Michaelsson J, Harris RA, et al. A structural basis for LCMV immune evasion: subversion of H-2D(b) and H-2K(b) presentation of gp33 revealed by comparative crystal structure Analyses. Immunity 2002;17:757-768 (Pubitemid 35477795)
20. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 1993;26:795-800.
21. McCoy AJ. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D Biol Crystallogr 2007;63:32-41.
22. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126-2132 (Pubitemid 41742764)
23. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximumlikelihood method. Acta Crystallogr D Biol Crystallogr 1997;53:240-255
24. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-5592 (Pubitemid 24377694)
25. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996;156:3308-3314
26. Wang B, Sharma A, Maile R, Saad M, Collins EJ, Frelinger JA. Peptidic termini play a significant role in TCR recognition. J Immunol 2002;169:3137-3145 (Pubitemid 35013159)
27. Chen W, Fecondo J, McCluskey J. The structural influence of individual residues located within peptide antigen depends upon their sequence context. Mol Immunol 1994;31:1069-1075 (Pubitemid 24308683)
28. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994;180:1471-1483 (Pubitemid 24289620)
29. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-580
30. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005;174:2476-2480 (Pubitemid 40279657)
31. Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 2008;105:8061-8066 (Pubitemid 351904708)
32. Dougherty DA. Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 1996;271:163-168 (Pubitemid 26033294)
33. Mecozzi S, West AP, Jr., Dougherty DA. Cation-pi interactions in aromatics of biological and medicinal interest: electrostatic potential surfaces as a useful qualitative guide. Proc Natl Acad Sci U S A 1996;93: 10566-10571 (Pubitemid 26333027)
34. Brandl M, Weiss MS, Jabs A, Suhnel J, Hilgenfeld R. C-H. . .pi-interactions in proteins. J Mol Biol 2001; 307:357-77.
35. Steiner T, Koellner G. Hydrogen bonds with piacceptors in proteins: frequencies and role in stabilizing local 3D structures. J Mol Biol 2001;305:535-557 (Pubitemid 33032860)
36. Weiss MS, Jabs A, Hilgenfeld R. Peptide bonds revisited. Nat Struct Biol 1998;5:676.
37. Bhattacharyya R, Chakrabarti P. Stereospecific interactions of proline residues in protein structures and complexes. J Mol Biol 2003;331:925-940 (Pubitemid 36945445)
38. MacArthur MW, Thornton JM. Influence of proline residues on protein conformation. J Mol Biol 1991;218: 397-412.
39. Dahl AM, Beverley PC, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol 1996;157:239-246
40. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185:453-459 (Pubitemid 27078363)
41. Mennuni C, Calvaruso F, Facciabene A, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005; 117:444-455 (Pubitemid 41429568)
42. Prlic M, Hernandez-Hoyos G, Bevan MJ. Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. J Exp Med 2006;203:2135-2143 (Pubitemid 44352234)